Renal Research Institute, LLC

And since this show reads disclosures, the statement's lead author, Navdeep Tangri, holds an ownership interest in ClinRisk, a kidney risk prediction model the statement highlights.

One co-author works at the Renal Research Institute and holds Fresenius shares, and he also co-authored the anemia and hospitalization studies.

And the Mayo paper's senior author is a co-author of the ASN statement too.

Small world.

Dr. Wael Hussain sits on the Fresenius US Home Medical Advisory Board, and this review rates therapies that Fresenius sells.

Also, two of the six authors work at Fresenius Medical Care, and the lead author lists the Renal Research Institute first.

The manuscript's conflict of interest statement reads, "None."

Okay.

The authors cite estimates that fatal access bleeding causes something like half a percent of dialysis deaths.

From one US series, forty-four percent of those deaths happened at home and thirty-seven percent on the way to the hospital.

The paper is in CJASN, led by Zijun Dong, with Dr. Peter Kotanko as senior author from the Renal Research Institute in New York.

Same disclosure as before.